ST 001 - Synkangda Life
Alternative Names: ST-001 Synkangda LifeLatest Information Update: 06 Sep 2023
At a glance
- Originator Synkangda Life
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Arthritis
Most Recent Events
- 08 Aug 2023 ST 001 - Synkangda Life is available for licensing as of 31 Jul 2023. service@xkdbio.com
- 31 Jul 2023 Preclinical trials in Arthritis in China (Parenteral), prior to July 2023 (Synkangda Life pipeline, July 2023).